- Home
- CISS vs PRFX Comparison
CISS vs PRFX Comparison
Compare CISS & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | PRFX |
|---|---|---|
| Founded | 2022 | 2007 |
| Country | Greece | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 1.6M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CISS | PRFX |
|---|---|---|
| Price | $2.44 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 33.9K |
| Earning Date | 05-19-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.58 |
| 52 Week High | $6.06 | $3.71 |
Technical Indicators
Market Signals| Indicator | CISS | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 26.03 |
| Support Level | $2.04 | $1.26 |
| Resistance Level | $2.81 | $1.58 |
| Average True Range (ATR) | 0.41 | 0.12 |
| MACD | -0.17 | -0.02 |
| Stochastic Oscillator | 1.89 | 26.43 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.
About PRFX PainReform Ltd.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.